Treatment of refractory juvenile dermatomyositis with tacrolimus

Clinical Rheumatology

Volumn 27, Issue 11, 2008, Pages 1469-1471

  Hassan, Jihaan ^a   van der Net, Jan Jaap ^a   van Royen Kerkhof, Annet ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Juvenile dermatomyositis; Tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXYGEN; PREDNISOLONE; PREDNISONE; RITUXIMAB; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CASE REPORT; DERMATOMYOSITIS; DIAPHRAGM PARALYSIS; DISEASE ACTIVITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG PULSE THERAPY; DRUG RESPONSE; DYSPHAGIA; ERYTHEMA; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; JUVENILE DERMATOMYOSITIS; MALE; MUSCLE INJURY; MUSCLE STRENGTH; MUSCLE WEAKNESS; MYALGIA; PHYSICAL ACTIVITY; PRESCHOOL CHILD; PRIORITY JOURNAL; SKIN DEFECT; VASCULITIS;

CALCINEURIN; CHILD; CHILD, PRESCHOOL; DERMATOMYOSITIS; FEMALE; HUMANS; MALE; REMISSION INDUCTION; TACROLIMUS;

EID: 53849130619     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-0973-2     Document Type: Article

References (14)

1. Stringer E, Feldman BM (2006) Advances in the treatment of juvenile dermatomyositis. Curr Opin Rheumatol 18:503-506
2. Wallemacq PE, Verbeeck RK (2001) Comparative clinical pharmacokinetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40:283-295
3. Yocum DE, Furst DE, Kaine JL et al (2003) Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: A double-blind trial. Arthritis Rheum 48:3328-3337
4. Duddridge M, Powell RJ (1997) Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann Rheum Dis 56:690-692
5. Baumgart DC, Pintoffl JP, Sturm A et al (2006) Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol 101:1048-1056
6. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353:1762-1763
7. Wilkes MR, Sereika SM, Fertig N et al (2005) Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 52:2439-2446
8. Shimojima Y, Gono T, Yamamoto K et al (2004) Efficacy of tacrolimus in treatment of polymyositis associated with myasthenia gravis. Clin Rheumatol 23:262-265
9. Ochi S, Nanki T, Takada K et al (2005) Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis/dermatomyositis. Clin Exp Rheumatol 23:707-710
10. Mitsui T, Kuroda Y, Kunishige M, Matsumoto T (2005) Successful treatment with tacrolimus in a case of refractory dermatomyositis. Intern Med 44:1197-1179
11. Yamada A, Ohshima Y, Omata N et al (2004) Steroid-sparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr 163:561-562
12. Modesto C, Boronat M, Marsal S, Arnal-Guimera C (2003) FK-506 in the treatment of unresponsive juvenile dermatomyositis. Ann Rheum Dis 59:727-729
13. Martin NA, Modesto CC, Arnal GC et al (2006) Efficacy of tacrolimus (FK-506) in the treatment of recalcitrant juvenile dermatomyositis: study of 6 cases. Med Clin (Barc) 127:697-701
14. Davies TH, Ning YM, Sanchez ER (2005) Differential control of glucocorticoid receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the immunosuppressive ligand FK506. Biochemistry 44:2030-2038